Proceedings of the Tenth International Conference of Drug Regulatory Authorities (ICDRA) - Hong Kong, China, 24 - 27 June 2002
(2002; 166 pages) View the PDF document
Table of Contents
View the documentAbbreviations and acronyms used in this report
Open this folder and view contentsOpening ceremony
Open this folder and view contentsHerbal medicines
Open this folder and view contentsKeynote address
Open this folder and view contentsSafety of blood-derived products
Open this folder and view contentsAntimicrobial resistance - new initiatives
Open this folder and view contentsHarmonization I
Open this folder and view contentsHarmonization II
Open this folder and view contentsProtection of trial subjects in clinical trials
Open this folder and view contentsRegulating biotechnology products
Open this folder and view contentsRegulatory challenges: health sector reform and drug regulatory capacity
Open this folder and view contentsAccess to drugs and vaccines I
Close this folderAccess to drugs and vaccines II
View the documentTwenty-five years of essential medicines: progress and agenda for regulators
View the documentEssential drugs list: South African experience
View the documentThe role of government and essential drugs - Indonesian experience
View the documentThailand’s experience in access to medicines
View the documentCurrent vaccine shortages in the United States of America
View the documentExpanding access to essential medicines and vaccines: lessons learnt in Brazil
View the documentRecommendations
Open this folder and view contentsCounterfeit pharmaceutical products
Open this folder and view contentsHomoeopathy
Open this folder and view contentsSafety monitoring
Open this folder and view contentsE-Commerce
Open this folder and view contentsCurrent topics
Open this folder and view contentsRegulatory challenges of new technologies
View the documentList of participants
View the documentBack cover
 

Recommendations

1. Countries should implement programmes aimed at assuring the availability, accessibility, quality and rational use of essential medicines.

2. The Model List of Essential Medicines is a central element of national drug policies. WHO should continue to maintain the Model List and support countries in adapting it to their needs and national context. Selection of essential medicines should be based on safety, quality and efficacy in addition to accessibility.

3. Access to medicines is improved by competition brought about by generic products. Countries should take measures to foster the development of a competitive generic market.

4. Countries and WHO should further develop initiatives aimed at expanding the implementation of the concept of essential medicines to encompass both the public and private sectors.

5. Countries and WHO should intensify efforts aimed at improving access to vital medicines, particularly those used for HIV/AIDSrelated care and treatment.

6. Problems of vaccine availability are becoming more frequent. Countries and WHO should intensify their efforts to prevent supply shortages.

7. Countries and WHO should continue to study the impact of international trade agreements on access to medicines and initiatives aimed at promoting essential medicines and rational use.

8. Progress should be reported back to the ICDRA

 

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: October 7, 2014